What is the address of ESKA PHARMA?

The registered office of ESKA PHARMA is located at Antoine Dansaertstraat 1, 1000 Brussel.

Is ESKA PHARMA still active?

Yes. According to the CBE (28 September 2026) ESKA PHARMA is active, legal situation “Normale toestand”, started on 6 October 2011.

Is ESKA PHARMA registered on Peppol?

Yes, ESKA PHARMA is registered on the Peppol network with ID 0208:0840007528.

What is the enterprise number of ESKA PHARMA?

The enterprise number of ESKA PHARMA is BE0840007528.

When was ESKA PHARMA founded?

ESKA PHARMA was founded on 6 October 2011.

Is ESKA PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 October 2011; 4 annual accounts filed, latest fiscal year 2024.

How much profit did ESKA PHARMA make in 2024?

ESKA PHARMA posted a profit after taxes of € 56,965 in financial year 2024.

What is the revenue of ESKA PHARMA?

As a small company, ESKA PHARMA is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 115,416.

ESKA PHARMA (Private Limited) - Brussel - BE0840007528

Q: What does ESKA PHARMA do?

ESKA PHARMA is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 6 October 2011, 1 establishment.

Dossier ESKA PHARMA, printed on 28 September 2026 from databakkes.be/en/0840007528/eska-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 4 % of short-term debt in 2024; threshold 65 %.

Financials

Financial year 2024

ESKA PHARMA from Brussel, company number BE0840007528, closed financial year 2024 with a result of € 56,965 after tax. For that financial year ESKA PHARMA recorded a gross margin of € 115,416 and equity of € 584,730. Compared with financial year 2023, the result moved from € 18,170 to € 56,965. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 28, 2025.

What it is worth Growing

€ 584,730

▲ 11% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 56,965

▲ 214% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 716

▼ 94% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € 572,330.

Debts at end 2024

Bank debt ≈ 12 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 939,636

▼ 8% vs 2023

€ 80,390 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.

Owed to suppliers

€ 1,887

▲ 57% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 11,296

▼ 76% vs 2023

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 73,035 Gross margin 2021: € 73,035 First fiscal year in the series	€ 281,939 Gross margin 2022: € 281,939 ▲ 286% vs 2021 (€ 73,035) Favourable step	€ 93,262 Gross margin 2023: € 93,262 ▼ 67% vs 2022 (€ 281,939) Unfavourable step	€ 115,416 Gross margin 2024: € 115,416 ▲ 24% vs 2023 (€ 93,262) Favourable step	▲ 24%
Profit after taxes	€ 55,688 Profit after taxes 2021: € 55,688 First fiscal year in the series	€ 213,170 Profit after taxes 2022: € 213,170 ▲ 283% vs 2021 (€ 55,688) Favourable step	€ 18,170 Profit after taxes 2023: € 18,170 ▼ 91% vs 2022 (€ 213,170) Unfavourable step	€ 56,965 Profit after taxes 2024: € 56,965 ▲ 214% vs 2023 (€ 18,170) Favourable step	▲ 214%
Equity	€ 322,825 Equity 2021: € 322,825 First fiscal year in the series	€ 509,595 Equity 2022: € 509,595 ▲ 58% vs 2021 (€ 322,825) Favourable step	€ 527,765 Equity 2023: € 527,765 ▲ 4% vs 2022 (€ 509,595) Favourable step	€ 584,730 Equity 2024: € 584,730 ▲ 11% vs 2023 (€ 527,765) Favourable step	▲ 11%
Total debts	€ 1,474,994 Total debts 2021: € 1,474,994 First fiscal year in the series	€ 1,137,885 Total debts 2022: € 1,137,885 ▼ 23% vs 2021 (€ 1,474,994) Favourable step	€ 1,130,948 Total debts 2023: € 1,130,948 ▼ 1% vs 2022 (€ 1,137,885) Favourable step	€ 1,029,521 Total debts 2024: € 1,029,521 ▼ 9% vs 2023 (€ 1,130,948) Favourable step	▼ 9%
Cash	€ 624 Cash 2021: € 624 First fiscal year in the series	€ 3,858 Cash 2022: € 3,858 ▲ € 3,233 vs 2021 (€ 624) Favourable step	€ 11,124 Cash 2023: € 11,124 ▲ 188% vs 2022 (€ 3,858) Favourable step	€ 716 Cash 2024: € 716 ▼ 94% vs 2023 (€ 11,124) Unfavourable step	▼ 94%
Land & buildings	€ 704,545 Land & buildings 2021: € 704,545 First fiscal year in the series	€ 689,394 Land & buildings 2022: € 689,394 ▼ 2% vs 2021 (€ 704,545) Unchanged	€ 674,242 Land & buildings 2023: € 674,242 ▼ 2% vs 2022 (€ 689,394) Unchanged	€ 659,091 Land & buildings 2024: € 659,091 ▼ 2% vs 2023 (€ 674,242) Unchanged	▼ 2%
Retained profit	€ 310,425 Retained profit 2021: € 310,425 First fiscal year in the series	€ 497,195 Retained profit 2022: € 497,195 ▲ 60% vs 2021 (€ 310,425) Favourable step	€ 515,365 Retained profit 2023: € 515,365 ▲ 4% vs 2022 (€ 497,195) Favourable step	€ 572,330 Retained profit 2024: € 572,330 ▲ 11% vs 2023 (€ 515,365) Favourable step	▲ 11%
Dividend	€ 0 Dividend 2021: € 0 First fiscal year in the series	€ 26,400 Dividend 2022: € 26,400 Unchanged (€ 0) Unchanged	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 26,400) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 1,180,970 Bank debt 2021: € 1,180,970 First fiscal year in the series	€ 1,096,740 Bank debt 2022: € 1,096,740 ▼ 7% vs 2021 (€ 1,180,970) Favourable step	€ 1,018,792 Bank debt 2023: € 1,018,792 ▼ 7% vs 2022 (€ 1,096,740) Favourable step	€ 939,636 Bank debt 2024: € 939,636 ▼ 8% vs 2023 (€ 1,018,792) Favourable step	▼ 8%
Balance sheet total	€ 1,797,820 Balance sheet total 2021: € 1,797,820 First fiscal year in the series	€ 1,647,480 Balance sheet total 2022: € 1,647,480 ▼ 8% vs 2021 (€ 1,797,820) Unchanged	€ 1,658,713 Balance sheet total 2023: € 1,658,713 ▲ 1% vs 2022 (€ 1,647,480) Unchanged	€ 1,614,251 Balance sheet total 2024: € 1,614,251 ▼ 3% vs 2023 (€ 1,658,713) Unchanged	▼ 3%

Key figures of ESKA PHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to ESKA PHARMA?

What happened at ESKA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 28, 2025 New annual accounts for financial year 2024: profit of € 56,965 (▲ 214% vs 2023). filed late Source: NBB ↗
Oct 6, 2011 New establishment in Brussel. KBO
Oct 6, 2011 Start of the company according to the CBE. KBO

In short

From € 55,688 profit in 2021 to € 56,965 profit in 2024.

Paid € 100,037 in corporate taxes since 2021.

Best year ever: 2022, with € 213,170 profit.

Paid out € 26,400 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at ESKA PHARMA? We notify you, reason included.

Follow ESKA PHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Antoine Dansaertstraat 1

1000 Brussel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

Uniphar

€ 210,483 gross margin · 2024

SANDRA

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0840.007.528

VAT number

BE 0840.007.528

Registered office

Antoine Dansaertstraat 1, 1000 Brussel

Names & denominations

ESKA PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

6 October 2011

Peppol

Active · Active since 4 Dec 2025

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗